Kymasin up natural product inhibits osteoclastogenesis and improves osteoblast activity by modulating src and p38 mapk

HIGHLIGHTS

  • who: Laura Salvadori and collaborators from the Department Translational Medicine, University of Piemonte Orientale, Novara, Italy have published the research: KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK, in the Journal: Nutrients 2022, 3053 of 22/07/2022
  • what: The aim of this study is to assess the effectiveness of KYMASIN UP in the differentiation process and activity of OCs and OBs by using established in_vitro models consisting of the RAW 264.7 monocyte cell line conditioned with RANKL (receptor activator of nuclear factor kappa-B ligand . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?